[1]殷梦杰,付守忠,戴锋,等.肝动脉灌注化疗联合卡瑞利珠单抗及索拉非尼治疗中晚期肝癌的疗效与安全性分析 [J].介入放射学杂志,2024,33(11):1212-1217.
　YIN Mengjie,FU Shouzhong,DAI Feng,et al.Hepatic arterial infusion chemotherapy combined with carrelizumab and sorafenib for the treatment of advanced hepatocellular carcinoma：its clinical efficacy and safety[J].journal interventional radiology,2024,33(11):1212-1217.
点击复制

肝动脉灌注化疗联合卡瑞利珠单抗及索拉非尼治疗中晚期肝癌的疗效与安全性分析
()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
33
期数:
2024年11
页码:
1212-1217
栏目:
临床研究
出版日期:
2024-11-20

文章信息/Info

Title:
Hepatic arterial infusion chemotherapy combined with carrelizumab and sorafenib for the treatment of advanced hepatocellular carcinoma：its clinical efficacy and safety
作者:
殷梦杰; 付守忠; 戴锋; 王斌; 王晓维; 丁苇; 蒋逢辰; 沈建东
Author(s):
YIN Mengjie; FU Shouzhong; DAI Feng; WANG Bin; WANG Xiaowei; DING Wei; JIANG Fengchen; SHEN Jiandong.
Department of Vascular Intervention，Affiliated Nantong Third Hospital of Nantong University （Nantong Municipal Third People′s Hospital），Nantong，Jiangsu Province 226001，China
关键词:
【关键词】肝细胞癌; 肝动脉灌注化疗; 安全性; 疗效
文献标志码:
A
摘要:
【摘要】目的探讨肝动脉灌注化疗（HAIC）联合索拉非尼及卡瑞利珠单抗治疗中晚期肝细胞癌（HCC）的有效性及安全性。方法收集2019年8月到2020年8月在南通大学附属南通第三医院接受HAIC联合卡瑞利珠单抗及索拉非尼治疗的36例HCC患者的临床资料，根据改良实体瘤临床疗效评价标准（mRECIST）评估联合治疗后的客观缓解率（ORR）和疾病控制率（DCR），采用美国国家癌症研究所制定的不良事件评价标准5.0版评估治疗的安全性。结果4周期的FOLFOX-HAIC治疗后患者的ORR、DCR分别是38.9%、77.8%；随访观察30个月，患者中位无进展生存期（mPFS）306 d（95%CI：242.7～369.3），中位总生存期（mOS）为515 d（95%CI：482.5～547.5）。1例患者经治疗后成功转化行外科手术治疗。总体不良事件100%，其中3级以上不良事件9例（25%），包括严重腹痛2例（5.6%），恶心1例（2.8%），呕吐1例（2.8%），谷丙转氨酶升高3例（8.3%），谷草转氨酶升高1例（2.8%），因发生严重免疫性肺炎导致肺功能衰竭死亡1例（2.8%）。结论中晚期肝癌采用肝动脉灌注化疗联合卡瑞利珠和索拉非尼治疗具有较好的肿瘤客观缓解率和疾病控制率，且安全性可控，为中晚期肝癌的治疗提供了新的选择，但患者长期生存获益有待更大样本量研究证实。

参考文献/References:

［1］Sung H，Ferlay J，Siegel RL，et al.Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin，2021，71：209-249.
［2］Siegel RL，Miller KD，Wagle NS，et al.Cancer statistics,2023［J］.CA Cancer J Clin，2023，73：17-48.
［3］Reig M，Forner A，Rimola J，et al.BCLC strategy for prognosis prediction and treatment recommendation：the 2022 update［J］.J Hepatol，2022，76：681-693.
［4］Lyu N，Kong Y，Mu L，et al.Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs.sorafenib for advanced hepatocellular carcinoma［J］.J Hepatol，2018，69：60-69.
［5］Li QJ，He MK，Chen HW，et al.Hepatic arterial infusion of oxaliplatin，fluorouracil，and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma：a randomized phase Ⅲ trial［J］.J Clin Oncol，2022，40：150-160.
［6］He M，Li Q，Zou R，et al.Sorafenib plus hepatic arterial infusion of oxaliplatin，fluorouracil，and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion：a randomized clinical trial［J］.JAMA Oncol，2019，5：953-960.
［7］Lai Z，He M，Bu X，et al.Lenvatinib，toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma：a biomolecular exploratory，phase Ⅱ trial［J］.Eur J Cancer，2022，174：68-77.
［8］Freites-Martinez A，Santana N，Arias-Santiago S，et al.Using the common terminology criteria for adverse events（CTCAE-Version 5.0）to evaluate the severity of adverse events of anticancer therapies.CTCAE version 5.0.evaluacion de la gravedad de los eventos adversos dermatologicos de las terapias antineoplasicas［J］.Actas Dermosifiliogr （Engl Ed），2021，112：90-92.
［9］Finn R，Qin S，Ikeda M，et al.Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma［J］.N Engl J Med，2020，382：1894-1905.
［10］Rizzo A，Dadduzio V，Ricci AD，et al.Lenvatinib plus pembrolizumab：the next frontier for the treatment of hepatocellular carcinoma?［J］.Expert Opin Investig Drugs，2022，31：371-378.
［11］Zheng K，Zhu X，Fu S，et al.Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib for hepatocellular carcinoma with major portal vein tumor thrombosis：a randomized trial［J］.Radiology，2022，303：455-464.
［12］谢海翔，韩创业，彭凯，等.肝动脉灌注化疗联合免疫靶向新辅助治疗单发CNLC Ⅰb期肝细胞癌的安全性与疗效分析［J］.中华肝胆外科杂志，2023，29：28-33.
［13］Ueshima K，Ogasawara S，Ikeda M，et al.Hepatic arterial infusion chemotherapy versus sorafenib in patients with advanced hepatocellular carcinoma［J］.Liver Cancer，2020，9：583-595.
［14］Lyu N，Wang X，Li JB，et al.Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma：a biomolecular exploratory，randomized，phase Ⅲ trial （FOHAIC-1）［J］.J Clin Oncol，2022，40：468-480.
［15］Fu Y，Peng W，Zhang W，et al.Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis［J］.J Gastroenterol，2023，58：413-424.
［16］Zhang TQ，Geng ZJ，Zuo MX，et al.Camrelizumab （a PD-1 inhibitor） plus apatinib （an VEGFR-2 inhibitor） and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C （TRIPLET）：a phase Ⅱ study［J］.Signal Transduct Target Ther，2023，8：413.
［17］Chen L，Flies DB.Molecular mechanisms of T cell co-stimulation and co-inhibition［J］.Nat Rev Immunol，2013，13：227-242.
［18］杨俊，印于，张申，等.HAIC序贯TAE治疗不可切除肝细胞癌的安全性和有效性［J］.介入放射学杂志，2023，32：229-232.
［19］中国医师协会肝癌专业委员会.中国肝细胞癌合并门静脉癌栓诊疗指南（2021年版）［J］.中华医学杂志，2022，102：243-254.
［20］石银生，方剑，姜继华，等.TACE联合卡瑞利珠单抗及阿帕替尼治疗晚期肝细胞癌的临床研究［J］.肝胆胰外科杂志，2023，35：731-735.

相似文献/References:

[1]李晓光,金征宇,潘杰,等.肝动脉化疗或栓塞治疗胰腺神经内分泌肿瘤肝转移的疗效分析[J].介入放射学杂志,2010,(06):442.
　LI Xiaoguang,JIN Zhengyu,PAN Jie,et al.Hepatic transarterial chemoperfusion and chemoembolization for the treatment of liver metastases from pancreatic neuroendocrine tumors：a therapeutic analysis[J].journal interventional radiology,2010,(11):442.
[2]陈伟敏,罗佐权.肝癌肝动脉灌注化疗与静脉输注硫代硫酸钠的“双路”疗法18例报告[J].介入放射学杂志,1992,(01):26.
[3]牛树茂,徐元贞,赵殿有,等.肝动脉灌注化疗后引起带状疱疹样皮疹六例报告[J].介入放射学杂志,1994,(01):54.
[4]秦伟,巫北海.5-FUDR经肝动脉灌注致硬化性胆管炎[J].介入放射学杂志,1996,(01):59.
[5]王有枝,李彦豪,梅雀林,等.原发性肝癌肝动脉化疗栓塞术后继发溶血性尿毒综合征3例并文献复习[J].介入放射学杂志,2016,(06):543.
　WANG You-zhi,LI Yan-hao,MEI Que-lin,et al.Secondary hemolytic uremic syndrome occurring after transcatheter arterial chemoembolization for primary hepatocellular carcinoma: report of 3 cases with literature review [J].journal interventional radiology,2016,(11):543.
[6]中国抗癌协会肿瘤介入学专业委员会,中国抗癌协会肿瘤介入学专业委员会化疗与免疫治疗分委会.改良式经皮肝动脉化疗药盒植入技术中国专家共识（2022版）[J].介入放射学杂志,2022,31(07):633.
　Professional Committee of Oncology Intervention,China Anti-Cancer Association,Chinese expert consensus on the modified implantation technique of port-catheter system for percutaneous hepatic arterial infusion chemotherapy（version 2022）[J].journal interventional radiology,2022,31(11):633.
[7]蒋健强,李晓娟,李拥军,等.白蛋白-胆红素评分在预测TACE治疗巨块型肝细胞癌后肝功能衰竭中的应用[J].介入放射学杂志,2023,32(01):55.
　JIANG Jianqiang,LI Xiaojuan,LI Yongjun,et al.The application of albumin-bilirubin score in predicting liver failure after transarterial chemoembolization for massive hepatocellular carcinoma [J].journal interventional radiology,2023,32(11):55.
[8]刘　晟,周平盛,沈　强,等.超声引导下微波消融术治疗特殊部位与非特殊部位单发肝细胞癌的疗效对比[J].介入放射学杂志,2023,32(01):36.
　LIU Sheng,ZHOU Pingsheng,SHEN Qiang,et al.Ultrasound-guided microwave ablation for the treatment of single hepatocellular carcinoma located at specific area and at non-specific area: comparison of clinical efficacy[J].journal interventional radiology,2023,32(11):36.
[9]王　曦,冯　苏,李　红,等.免疫检查点抑制剂联合TACE在肝癌治疗中的研究进展[J].介入放射学杂志,2023,32(01):90.
　WANG Xi,FENG Su,LI Hong,et al.Research progress in immune checkpoint inhibitors combined with TACE for the treatment of hepatocellular carcinoma[J].journal interventional radiology,2023,32(11):90.
[10]徐永康,付舒敏,李　丹,等.肝动脉灌注化疗联合系统治疗在原发性肝癌中的研究进展[J].介入放射学杂志,2023,32(01):94.
　XU Yongkang,FU Shumin,LI Dan,et al.Research progress in hepatic arterial infusion chemotherapy combined with systemic therapy for the treatment of primary hepatocellular carcinoma[J].journal interventional radiology,2023,32(11):94.
[11]张岩基,王汇源,李浩,等.经导管动脉化疗栓塞和肝动脉灌注化疗治疗肝细胞癌现状和进展[J].介入放射学杂志,2024,33(09):1039.
　ZHANG Yanji,WANG Huiyuan,LI Hao,et al.Current status and progress of TACE and HAIC in the treatment of hepatocellular carcinoma[J].journal interventional radiology,2024,33(11):1039.
[12]杜楠,王英,李文涛.肝癌TACE还是HAIC？[J].介入放射学杂志,2024,33(12):1269.
　DU Nan,WANG Ying,LI Wentao..Treatment of hepatocellular carcinoma：TACE or HAIC？[J].journal interventional radiology,2024,33(11):1269.

备注/Memo

备注/Memo:
（收稿日期：2024-01-29）
（本文编辑：茹实）
更新日期/Last Update: 2024-11-20